Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial
- Resource Type
- Article
- Source
- The Lancet HIV; December 2018, Vol. 5 Issue: 12 pe715-e722, 8p
- Subject
- Language
- ISSN
- 24054704; 23523018